- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05911633
BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC) (BIOPEARL-ONE)
February 22, 2024 updated by: Terumo Europe N.V.
BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC): Prospective, Single Arm, Multi-center, Post-Market Clinical Follow-up (PMCF) Study
The primary objective of the study is to confirm technical success and safety of BioPearl™ microspheres loaded with Doxorubicin in the treatment of unresectable hepatocellular carcinoma (HCC).
The secondary objective of the study is to investigate the efficacy of BioPearl™ microspheres loaded with Doxorubicin in the treatment of subjects with unresectable HCC.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, single arm, multi-centre, post-market clinical follow-up study to further assess safety and efficacy in 50 subjects with unresectable HCC treated with BioPearl™ microspheres loaded with Doxorubicin.
All subjects will undergo clinical follow-up until disease progression and/or next treatment option, after which subjects will be followed for survival.
Subjects will be followed up to a maximum of 18 months.
An intermediate analysis will take place during enrollment period on safety and technical success to support regulatory requirements.
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Brussels, Belgium
- Not yet recruiting
- CUB Hôpital Erasme
-
Contact:
- Gotran Verset, MD
-
Leuven, Belgium
- Recruiting
- UZ Leuven
-
Contact:
- Geert Maleux, MD
- Phone Number: 0032 16 34 75 78
- Email: geert.maleux@uzleuven.be
-
-
-
-
-
Heilbronn, Germany
- Recruiting
- SLK-Kliniken Heilbronn
-
Contact:
- Philippe Pereira, MD
- Phone Number: 07131 49-466-63
- Email: Philippe.Pereira@slk-kliniken.de
-
-
-
-
-
Milan, Italy
- Recruiting
- Fondazione IRCCS Instituto Tumori
-
Contact:
- Carlo Spreafico, MD
- Phone Number: 39 02 23901
- Email: Carlo.Spreafico@istitutotumori.mi.it
-
Rome, Italy
- Not yet recruiting
- Fondazione Policlinico Universitario A. Gemelli
-
Contact:
- Roberto Iezzi, MD
-
Turin, Italy
- Not yet recruiting
- Città della Salute e della Scienza di Torino Presidio Molinette
-
Contact:
- Paolo Fonio, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subject is at least 18 years old
- Subject with HCC confirmed by histology or according to the latest applicable version of (EASL (the European Association for the Study of the Liver) criteria
- Subject with tumor(s) < 5 cm and within the up to 7 criteria: the sum of the diameter of the largest tumor (in cm) and the number of tumors must be ≤ 7 (see appendix E)
- BCLC (Barcelona Clinic Liver Cancer) B subject or BCLC A subject not a candidate for curative treatment at the time of study inclusion or who has failed/recurred after resection/ablation. Recurrence in the segment of RFA (Radiofrequency Ablation is not allowed
- WHO (World Health Organization) or ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1
- Subject deemed treatable in one session for initial treatment
- Normal liver or compensated cirrhosis with preserved liver function (Child-Pugh Class A)
- Total bilirubin ≤ 2.0 mg/dl
- Adequate bone marrow function: Hemoglobin ≥ 9g/dl, absolute neutrophil count ≥ 1.0 x 109/L, platelet count ≥ 75 x 109/L
- Subject with no ascites or with minor ascites controlled by sodium dietary restrictions (subject receiving diuretic treatment or paracentesis is not eligible)
- Adequate renal function: serum creatinine < 1.5 X ULN (Upper Limit of Normal)
- Subject has provided written informed consent
- Subjects of childbearing/reproductive potential should use adequate birth control measures, during the study treatment period until survival follow-up
Exclusion Criteria:
- Subject previously treated with any systemic therapy for HCC
- Subject previously treated with intra-arterial loco-regional therapy for HCC
- Prior resection/ablation is allowed as per inclusion criteria 4
- Eligible for curative treatment at the time of study inclusion
- Advanced liver disease: Child-Pugh's B-C class or active gastrointestinal bleeding, encephalopathy
- Advanced tumoral disease: BCLC class C or D (vascular invasion - even segmental, extra-hepatic spread or cancer-related symptoms performance status >1)
- History of another primary tumor. Exceptions include: 1) Malignancy treated with curative intent ≥ 5 years before inclusion and with no known active disease / 2) Malignancy which occurred < 5 years before, not active and not expected to recur or be clinically relevant in the next 5 years
- Subject with history of biliary tree disease or biliary dilatation
- Portal vein thrombosis, porto-systemic shunt, hepatofugal blood flow or absent portal blood flow in the liver area to be treated
- Contraindication to multiphasic CT and MRI (e.g. allergy to contrast media)
- Any other contraindication for embolization procedure or Doxorubicin treatment
- Subject is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints Note: Trials requiring extended follow-up for products that were investigational, but have become commercially available since then, are not considered investigational trials
- In the Investigator's opinion subject has (a) co-morbid condition(s) that could limit the subject's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study
- Pregnant or breast-feeding woman
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single arm
Transarterial Chemo Embolization (TACE) with BioPearl™ microspheres loaded with Doxorubicin
|
TACE
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: by evaluating all procedural or study device related grade 3-4-5 adverse events
Time Frame: Day 29
|
Safety: by evaluating all procedural or study device related grade 3-4-5 adverse events (AEs) during a period of 4 weeks post initial treatment as per local investigator assessment
|
Day 29
|
Technical success
Time Frame: Day 1
|
Ability to reach near stasis in the treated tumor feeding arteries during chemoembolization procedure
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor response rate
Time Frame: 18 months
|
Assessed by mRECIST (modified Response Evaluation Criteria in Solid Tumors) criteria at 4 weeks and every 3 months as per local investigator assessment
|
18 months
|
Progression Free Survival (PFS
Time Frame: 18 months
|
Defined as time from the treatment to disease progression according to mRECIST criteria or death from any cause, whichever occurs first as per local investigator assessment
|
18 months
|
Time to progression of treated tumor(s)
Time Frame: 18 months
|
Defined as time from treatment to progression of the treated lesion according to mRECIST criteria as per local investigator assessment
|
18 months
|
Duration of response
Time Frame: 18 months
|
According to mRECIST as per local investigator assessment
|
18 months
|
Best overall response
Time Frame: 18 months
|
Defined as best response of treated tumor(s) recorded during the study according to mRECIST criteria as per local investigator assessment
|
18 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
February 29, 2024
Primary Completion (Estimated)
June 30, 2026
Study Completion (Estimated)
November 30, 2027
Study Registration Dates
First Submitted
May 26, 2023
First Submitted That Met QC Criteria
June 20, 2023
First Posted (Actual)
June 22, 2023
Study Record Updates
Last Update Posted (Actual)
February 23, 2024
Last Update Submitted That Met QC Criteria
February 22, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- T144E3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma Non-resectable
-
Omega TherapeuticsRecruitingHepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-ResectableUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
Institut für Klinische Krebsforschung IKF GmbH...IpsenRecruitingHepatocellular Carcinoma Non-resectable | Metastatic Hepatocellular CarcinomaGermany
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer Network; AVEO...CompletedAdvanced Adult Hepatocellular Carcinoma | Non-Resectable Hepatocellular CarcinomaUnited States
-
Second Affiliated Hospital of Guangzhou Medical...Recruiting
-
Tongji HospitalGeneplus-Beijing Co. Ltd.RecruitingHepatocellular Carcinoma Non-resectableChina
-
Assistance Publique - Hôpitaux de ParisLaboratoire EISAINot yet recruitingHepatocellular Carcinoma Non-resectableFrance
-
Wan-Guang ZhangThe Second Affiliated Hospital of Fujian Medical University; Geneplus-Beijing... and other collaboratorsRecruitingHepatocellular Carcinoma Non-resectableChina
-
Zhujiang HospitalNot yet recruitingHepatocellular Carcinoma Non-resectable
-
Jinan Military General HospitalRecruitingHepatocellular Carcinoma Non-resectableChina
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHepatocellular Carcinoma Non-ResectableChina
Clinical Trials on BioPearl™
-
BaroNova, Inc.Completed
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalUnknownBrain Damage, Chronic | Cerebellar Cognitive Affective Syndrome | Cerebellar Mutism
-
Asklepios Kliniken Hamburg GmbHUniversity of KielCompletedAirway Management | Laryngeal Mask Airway | Fibreoptic Intubation
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting,...RecruitingHydrocephalus | Hydrocephalus, CommunicatingArgentina
-
Medtronic CardiovascularActive, not recruitingAortic AneurysmGermany, New Zealand, United States, Netherlands, Switzerland, United Kingdom, Spain, Australia, Italy, Sweden, France, Austria, Slovakia
-
Gülçin Özalp GerçekerCompletedCatheter Complications | Catheter LeakageTurkey
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalUnknownTemporal Lobe Epilepsy
-
GlaxoSmithKlineCompletedTetanus | Diphtheria | Acellular Pertussis | Poliomyelitis | Haemophilus Influenzae Type bKorea, Republic of
-
GlaxoSmithKlineCompletedHepatitis B | Hepatitis AGermany, Belgium, Czechia
-
Medtronic CardiovascularMedtronicCompletedAortic StenosisNew Zealand, United Kingdom, Australia